bioRxivBiochemistry
Staphylococcus aureus Cas9 is a multiple-turnover enzyme
P. Yourik, R. T. Fuchs, M. Mabuchi, J. L. Curcuru, G. B. Robb
Abstract
Cas9 nuclease is the key effector of type II CRISPR adaptive immune systems found in bacteria. The nuclease can be programmed by a single guide RNA (sgRNA) to cleave DNA in a sequence-specific manner. This property has led to its widespread adoption as a genome editing tool in research laboratories and holds great promise for biotechnological and therapeutic applications. The general mechanistic features of catalysis by Cas9 homologs are comparable; however, a high degree of diversity exists among the protein sequences, which may result in subtle mechanistic differences. S. aureus (SauCas9) and especially S. pyogenes (SpyCas9) are among the best-characterized Cas9 proteins and share about 17% sequence identity. A notable feature of SpyCas9 is an extremely slow rate of reaction turnover, which is thought to limit the amount of substrate DNA cleavage. Using in vitro biochemistry and enzyme kinetics we directly compare SpyCas9 and SauCas9 activities. Here, we report that in contrast to SpyCas9, SauCas9 is a multiple-turnover enzyme, which to our knowledge is the first report of such activity in a Cas9 homolog. We also show that DNA cleaved with SauCas9 does not undergo any detectable single-stranded degradation after the initial double-stranded break observed previously with SpyCas9, thus providing new insights and considerations for future design of CRISPR/Cas9-based applications.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- High-throughput in vitro specificity profiling of natural and high-fidelity CRISPR-Cas9 variants
K. Murugan, A. S. Seetharam, … D. G. Sashital·bioRxiv·May 12, 2020
- Characterization of Streptococcus uberis Cas9 (SuCas9) - a Type II-A Ortholog Functional in Human Cells
Aleksandra Vasileva, Marina Abramova, … Konstantin Severinov·The CRISPR JournalPeer-reviewed·Dec 30, 2025
- Potent CRISPR-Cas9 inhibitors from Staphylococcus genomes
K. E. Watters, H. Shivram, … J. A. Doudna·bioRxiv·Oct 9, 2019
- Pairwise library screen systematically interrogates Staphylococcus aureus Cas9 specificity in human cells
J. Tycko, L. A. Barrera, … P. D. Hsu·bioRxiv·Feb 22, 2018
- DNA unwinding is the primary determinant of CRISPR-Cas9 activity
S. Gong, H. H. Yu, … D. W. Taylor·bioRxiv·Oct 19, 2017
- Massively parallel kinetic profiling of natural and engineered CRISPR nucleases
Stephen K. Jones, John A. Hawkins, … Ilya J. Finkelstein·Nature BiotechnologyPeer-reviewed·Sep 7, 2020